Artwork
iconShare
 
Manage episode 521124489 series 32428
Content provided by SWI swissinfo.ch. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by SWI swissinfo.ch or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Send us a text

We trace how a soil-derived drug led to the discovery of mTOR, why growth control sits at the core of aging biology, and where evidence ends for humans. Michael Hall’s quiet breakthroughs explain fasting, autophagy, and rapamycin without the hype.

To read more about this topic and for more science stories, visit our website swisinfo.ch. You can help other people to find our podcast by leaving us a five-star review.
Journalist: Jessica Davis Plüss
Host: Jo Fahy
Audio editor/video journalist: Michele Andina
Distribution and Marketing: Xin Zhang

SWI swissinfo.ch is a public service media company based in Bern, Switzerland.

  continue reading

Chapters

1. Setting The Longevity Question (00:00:00)

2. Meeting Michael Hall In Basel (00:02:02)

3. Blue Zones And Early Skepticism (00:03:57)

4. From Nuclear Transport To Drug Mysteries (00:06:37)

5. Why Yeast Cracked A Human Problem (00:09:12)

6. The TOR Genes And Controlled Growth (00:11:02)

7. mTOR, Nutrients, And Aging Links (00:14:12)

8. Animal Evidence For Rapamycin (00:16:42)

9. Humans, Hype, And Trial Limits (00:18:52)

104 episodes